• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Drug-Device Combinations

One Drop touts study of digital diabetes management platform, plans to develop sensor

April 28, 2022 By Sean Whooley

One Drop

One Drop announced today that new peer-reviewed research demonstrates sustained blood glucose reductions with its diabetes platform. New York-based One Drop presented the clinical health outcomes associated with the long-term use of its digital diabetes offering at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The results demonstrated clinically sustained and […]

Filed Under: Big Data, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: One Drop

Walmart unveils telehealth offering for managing diabetes

April 28, 2022 By Sean Whooley

Walmart Health Virtual Care Diabetes Program

Walmart announced today that its MeMD national telehealth provider partner launched the Walmart Health Virtual Care Diabetes Program. The platform, available as a standalone or as part of a comprehensive medical and behavioral telehealth program, was developed for employers and payors to help their employees and members close gaps in diabetes management among employees and […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: American Diabetes Association, Walmart

Analysis backs use of Abbott’s FreeStyle Libre CGM in type 1, type 2 diabetes

April 28, 2022 By Sean Whooley

Abbott FreeStyle Libre CGM

Abbott (NYSE:ABT) announced today that a new real-world meta-analysis provided positive data for its FreeStyle Libre system. The analysis of 75 real-world observational studies of the FreeStyle Libre continuous glucose monitoring (CGM) system demonstrated significant reductions in glycated hemoglobin (HbA1c) sustained for up to 24 months in adults with both type 1 and type 2 […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott

Study results show improved time in range with Diabeloop automated insulin delivery system

April 28, 2022 By Sean Whooley

Diabeloop logo - large

Diabeloop announced today that study data support the use of its DBLG1 hybrid closed-loop automated insulin delivery system. Paris-based Diabeloop’s real-life German cohort data, presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona, show a constant improvement in time in range (70-180 mg/dL) combined with a significant reduction of hypoglycemia. According […]

Filed Under: Auto-injectors, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Diabeloop

Study supports use of PharmaJet’s needle-free vaccine delivery systems

April 27, 2022 By Sean Whooley

PharmaJet Stratis

PharmaJet announced today that study data demonstrated increased immunogenicity when using its needle-free delivery system. Golden, Colorado-based PharmaJet presented the research results for the needle-free vaccine injection technology last week at the World Vaccine Congress. PharmaJet’s needle-free systems have been incorporated into clinical studies for multiple RNA and DNA vaccine and therapeutic development programs thanks […]

Filed Under: Auto-injectors, Clinical Trials, Drug-Device Combinations, Pharmaceuticals Tagged With: PharmaJet

Study shows sustained improvements with Medtronic’s MiniMed 780G with Guardian 4

April 27, 2022 By Sean Whooley

Medtronic MiniMed 780G

Medtronic (NYSE:MDT) announced today that the extended study phase of its MiniMed 780G insulin pump system produced positive data. Fridley, Minnesota-based Medtronic presented new data from the study of MiniMed 780G with the no-calibration, non-adjunctive Guardian 4 sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona. Data demonstrated sustained improvements in […]

Filed Under: Auto-injectors, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Medtronic

Abbott, Camdiab, Ypsomed forge partnership for automated insulin delivery

April 27, 2022 By Sean Whooley

Abbott FreeStyle Libre 3 CamDiab Ypsomed ypsopump

Abbott (NYSE:ABT) announced today that it partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system. The companies announced the partnership at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. It seeks to develop and commercialize the integrated AID system with an initial focus centered around […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott, CamDiab, Ypsomed

Insulet announces positive study data for Omnipod 5 for type 1, type 2 diabetes

April 27, 2022 By Sean Whooley

Insulet Omnipod 5 Dexcom G6

Insulet (Nasdaq:PODD) today unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes. Acton, Massachusetts-based Insulet presented results from studies as well as user experience data for both type 1 and type 2 diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, […]

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Insulet

Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation

April 25, 2022 By Sean Whooley

Impel Neuropharma logo updated

Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand. Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Impel NeuroPharma Inc., Impel Pharmaceuticals

EMA gives positive opinion on Novo Nordisk’s human insulin with flexible storage

April 25, 2022 By Sean Whooley

Novo Nordisk

Novo Nordisk (NYSE:NVO) announced that the European Medicines Agency (EMA) granted a positive opinion on a storage update for insulin. EMA’s positive opinion relates to a proposed update to the storage conditions of two human insulins: Actrapid (short-acting insulin) and Insulatard (intermediate-acting insulin). Bagsværd, Denmark-based Novo Nordisk said in a news release that the EMA’s […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance Tagged With: Novo Nordisk

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 242
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS